Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Postherpetic Neuralgia Overview | 9 | 1 |
| Therapeutics Development | 10 | 1 |
| Pipeline Products for Postherpetic Neuralgia Overview | 10 | 1 |
| Postherpetic Neuralgia Therapeutics under Development by Companies | 11 | 2 |
| Postherpetic Neuralgia Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Postherpetic Neuralgia Products under Development by Companies | 16 | 1 |
| Postherpetic Neuralgia Companies Involved in Therapeutics Development | 17 | 16 |
| Aestus Therapeutics, Inc. | 17 | 1 |
| ContraVir Pharmaceuticals, Inc. | 18 | 1 |
| Daewoong Pharmaceutical Co., Ltd. | 19 | 1 |
| Daiichi Sankyo Company, Limited | 20 | 1 |
| Immune Pharmaceuticals Inc. | 21 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 22 | 1 |
| KPI Therapeutics, Inc. | 23 | 1 |
| Lpath, Inc. | 24 | 1 |
| Merck &Co., Inc. | 25 | 1 |
| Patagonia Pharmaceuticals, LLC | 26 | 1 |
| Pfizer Inc. | 27 | 1 |
| Phosphagenics Limited | 28 | 1 |
| Relmada Therapeutics, Inc. | 29 | 1 |
| Scilex Pharmaceuticals, Inc. | 30 | 1 |
| Teva Pharmaceutical Industries Ltd. | 31 | 1 |
| Toray Industries, Inc. | 32 | 1 |
| Postherpetic Neuralgia Therapeutics Assessment | 33 | 12 |
| Assessment by Monotherapy Products | 33 | 1 |
| Assessment by Combination Products | 34 | 1 |
| Assessment by Target | 35 | 3 |
| Assessment by Mechanism of Action | 38 | 3 |
| Assessment by Route of Administration | 41 | 2 |
| Assessment by Molecule Type | 43 | 2 |
| Drug Profiles | 45 | 39 |
| (amitriptyline + ketamine hydrochloride) Drug Profile | 45 | 3 |
| (clonidine hydrochloride + naltrexone hydrochloride) Drug Profile | 48 | 1 |
| ATX-08001 Drug Profile | 49 | 2 |
| bupivacaine hydrochloride Drug Profile | 51 | 2 |
| C-746 Drug Profile | 53 | 1 |
| DWP-05195 Drug Profile | 54 | 1 |
| funapide Drug Profile | 55 | 2 |
| FV-100 Drug Profile | 57 | 4 |
| ketoprofen Drug Profile | 61 | 1 |
| lidocaine hydrochloride Drug Profile | 62 | 1 |
| lidocaine hydrochloride patch Drug Profile | 63 | 1 |
| Lpathomab Drug Profile | 64 | 3 |
| mepivacaine hydrochloride Drug Profile | 67 | 1 |
| mirogabalin besylate Drug Profile | 68 | 2 |
| MK-8291 Drug Profile | 70 | 1 |
| naltrexone hydrochloride Drug Profile | 71 | 1 |
| PATN-02 Drug Profile | 72 | 1 |
| pregabalin CR Drug Profile | 73 | 2 |
| pregabalin SR Drug Profile | 75 | 1 |
| REL-1017 Drug Profile | 76 | 3 |
| TRK-700 Drug Profile | 79 | 1 |
| U-2902 Drug Profile | 80 | 2 |
| zucapsaicin Drug Profile | 82 | 2 |
| Postherpetic Neuralgia Dormant Projects | 84 | 3 |
| Postherpetic Neuralgia Discontinued Products | 87 | 1 |
| Postherpetic Neuralgia Product Development Milestones | 88 | 9 |
| Featured News &Press Releases | 88 | 1 |
| Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles | 88 | 1 |
| May 12, 2016: SCILEX Pharmaceuticals Study Suggests Underutilization of Recommended First-Line Lidocaine Patches and Opioid Overuse for Treatment of Pain Associated with Post-Herpetic Neuralgias | 88 | 1 |
| Apr 22, 2016: SCILEX Pharmaceuticals Reports First-Line Treatments Including Lidocaine Patches for Post-Herpetic Neuralgia Are Significantly Underutilized | 89 | 1 |
| Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study | 90 | 1 |
| Dec 10, 2015: SCILEX Pharmaceuticals Announces Executive Hires | 90 | 1 |
| Sep 16, 2015: FDA Accepts SCILEX Pharmaceuticals' NDA Filing for ZTlido | 91 | 1 |
| Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial | 91 | 1 |
| Apr 02, 2015: Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia | 91 | 1 |
| Feb 20, 2015: ContraVir Pharmaceuticals Provides Clinical Update on FV-100 | 92 | 1 |
| Feb 19, 2015: Xenon Pharmaceuticals Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia | 92 | 1 |
| Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin | 93 | 1 |
| Jan 07, 2015: ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100 | 94 | 1 |
| Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia | 94 | 1 |
| Aug 11, 2014: Scilex Pharmaceuticals Completes Trial Enrollment for Ztlido | 95 | 1 |
| Jul 14, 2014: SCILEX Pharmaceuticals Commences Dermal Safety Studies of Ztlido | 95 | 2 |
| Appendix | 97 | 2 |
| Methodology | 97 | 1 |
| Coverage | 97 | 1 |
| Secondary Research | 97 | 1 |
| Primary Research | 97 | 1 |
| Expert Panel Validation | 97 | 1 |
| Contact Us | 97 | 1 |
| Disclaimer | 98 | 1 |